DAIC

MARCH 13, 2024

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage.

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

DAIC

JANUARY 30, 2025

By integrating a real-time frailty risk score into the electronic medical record (EMR), presenting stroke severity and other variables, we can proactively identify who will benefit from immediate surgery and who may need pre-habilitating before surgery to achieve better outcomes.

Strokes 52

Strokes Stroke Outcomes Quality of Life 52

DAIC

JULY 25, 2024

BioCardia previously confirmed alignment with the United States Food and Drug Administration (FDA) on the design of the 250-patient randomized, controlled trial and the minimum of 12-month primary composite endpoint of all cause death, reduction in major adverse cardiovascular events, and improvement in quality of life.

Heart Failure 111

Heart Failure Quality of Life CMS Reimbursement 111

DAIC

MAY 2, 2024

Although prognosis of refractory angina has improved in recent years, patients with refractory angina experience a significantly impaired quality of life with disproportionately high utilization of healthcare services. These observations reflect the great need for new therapies for these patients.

Ischemia 95

Ischemia Angina Heart Failure Outcomes 95

American College of Cardiology

FEBRUARY 1, 2025

Cardiovascular medications frequently lead this category, often contributing to adverse clinical outcomes, including emergency department visits and hospitalizations. Clinicians working with older patients have witnessed firsthand how polypharmacy can complicate both their care and diminish quality of life.

Cardiovascular Disease 40

Cardiovascular Disease Coronary Artery Disease CMS Hospital 40

Stroke Journal

JANUARY 30, 2025

The Alzheimers Associations expert guidance is to avoid co-prescribing; however, CMS and FDA do not restrict or warn against it. Monthly model outcomes included ICH, ischemic stroke, cognitive impairment, quality-adjusted life months (QALMs), and survival. Increased ICH risk was a key input: a trial-reported 2.02-fold

Quality of Life 40

Quality of Life CMS Atrial Fibrillation Stroke 40

Stroke Journal

FEBRUARY 1, 2024

Introduction:There are significant and longstanding inequities in stroke prevalence and care as well as outcomes. Social determinants of health (SDOH) are known to be a risk factor in post-stroke recovery. SDOH also put individuals at higher risk for 90-day mortality. 12.5%, and 90-day readmissions ranging from 18.9%

Strokes 40

Strokes Stroke Quality of Life CMS 40